Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

6 years ago
Peer Review

MyoKar­dia re­claims US roy­al­ty rights to heart drugs, com­plet­ing con­scious un­cou­pling from Sanofi

6 years ago
R&D

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

6 years ago
Deals

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly ...

6 years ago
R&D

Pa­tient reg­istries may prove valu­able in reg­u­la­to­ry de­ci­sions, EMA study finds

6 years ago
FDA+

Pre­ci­sion Bio­Sciences backs off-the-shelf can­cer cell ther­a­py ef­fort with new man­u­fac­tur­ing plant

6 years ago
R&D

Cu­ri­ous case of stock price moves re­veals Sum­it­o­mo Dainip­pon is eye­ing $202M buy­out of Aus­tralian stem cell play­er

6 years ago
Deals

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

6 years ago
Financing

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league ...

6 years ago
People
R&D

Chardan's blank check com­pa­ny picks mi­cro­bio­me play­er Bio­mX for $70M re­verse merg­er

6 years ago
Startups

Ap­peal re­ject­ed, Shkre­li stays in jail; MyoKar­dia brings for­ward piv­otal da­ta read­out

6 years ago
News Briefing

FDA, EMA ad­vise on risk-based mon­i­tor­ing in clin­i­cal tri­als

6 years ago
FDA+

As Ac­thar trou­bles per­sist, Mallinck­rodt in­vests in RNAi and Si­lence Ther­a­peu­tics

6 years ago
R&D

Biotech uni­corns first to go as Neil Wood­ford auc­tions as­sets off sus­pend­ed fund — re­port

6 years ago
People
Financing

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M ...

6 years ago
Deals

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

6 years ago
Deals

Den­mark's Gen­mab hits the jack­pot with $500M+ US IPO as small­er biotechs rake in a com­bined $147M

6 years ago
Financing

FDA over­rides ad­comm opin­ions a fifth of the time, study finds — but why?

6 years ago
FDA+

Take­da preps an­oth­er drug auc­tion as ex­ecs look to fur­ther trim its post-Shire buy­out debt load — re­port

6 years ago
Deals
Pharma

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

6 years ago
Financing
Startups

Fol­low­ing foot­steps of chart-top­ping Chi­nese coun­ter­parts, Al­pham­ab On­col­o­gy files IPO at HKEX

6 years ago
Financing
China

Seer en­tices ex FDA com­mis­sion­er Mc­Clel­lan to its board; Van­da tests tradip­i­tant in mo­tion sick­ness study

6 years ago
News Briefing

With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

6 years ago
FDA+

The $1.1M good­bye: Gilead CSO John McHutchi­son is out as Daniel O’Day shakes up the se­nior team

6 years ago
People
First page Previous page 930931932933934935936 Next page Last page
A service from the Financial Times